Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C

American Journal of Gastroenterology

Volumn 93, Issue 12, 1998, Pages 2441-2444

  Sugano, Shigeo ^a   Suzuki, Tokuya ^a   Watanabe, Manabu ^a   Kenji, Ohe ^a   Ishii, Kunihiko ^a   Okajima, Tugio ^a  

^a Saiseikai Wakakusa Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COMPLEMENT COMPONENT C5A; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HEPATITIS C; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RETINA CAPILLARY; RETINA HEMORRHAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SYMPTOMATOLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; COMPLEMENT C5A; FEMALE; FUNDUS OCULI; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RETINAL DISEASES; RETINAL HEMORRHAGE;

EID: 0032433318     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00701.x     Document Type: Article

References (16)

1. 1. Renault PF, Hoofnagel JH. Side effects of alpha interferon. Semin Liver Dis 1989;9:273-7.
2. 2. IIno S, Hino K, Kuroki T, et al. Treatment of chronic hepatitis C with high-dose interferon-α-2b. A multicenter study. Dig Dis Sci 1993;38: 612-8.
3. 3. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
4. 4. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
5. 5. Guyer DG, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350-6.
6. 6. Sugano S, Yanagimoto M, Suzuki T, et al. Retinal complications with elevated circulating plasma C5a associated with interferon-α therapy for chronic active hepatitis C. Am J Gastroenterol 1994;89:2054-6.
7. 7. Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995;79:150-2.
8. 8. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91:309-13.
9. 9. Jacob HS, Goldstein IM, Shapiro I, et al. Sudden blindness in acute pancreatitis. Possible role of complement-induced retinal leukoembolization. Arch Intern Med 1981;141:134-6.
10. 10. Kincaid MC, Green WR, Knox DL, et al. A clinicopathological case report of retinopathy of pancreatitis. Br J Ophthalmol 1982;66:219-26.
11. 11. Shapiro I, Jacob HS. Leukoembolization in ocular vascular occlusion. Ann Ophthalmol 1982;14:60-2.
12. 12. Renfer L, Frank MM, Hammer CH, et al. A simplified method for purification of human C5a from citrated plasma. J Immunol Meth 1986;88:193-205.
13. 13. Wagner JL, Hugli TE. Radioimmunoassay for anaphylatoxins: A sensitive method for determining complement activation products in biological fluids. Analyt Biochem 1984;136:75-88.
14. 14. Pober JS. Cytokine-mediated activation of vascular endothelium. Am J Pathol 1988;133:426-33.
15. 15. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res 1983;53:557-73.
16. 16. Belmont HM, Hopkins P, Edelson HS, et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 1986;29: 1085-9.